Literature DB >> 24914474

Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.

Heiko Götte1, Margarita Donica, Giacomo Mordenti.   

Abstract

Choice of target population is an essential part at the design stage of clinical trials. Data from earlier clinical development might suggest that the treatment is more effective in a subpopulation, but there might not be enough evidence to restrict the target population upfront. Adaptive designs allow modification of the target population based on interim data. Decision for modification should be based on objective decision rules. The presented decision rules maximize the weighted probability of correct interim decisions based on prior assumptions. Evaluation of decision rules in the planning phase can improve probabilities of correct interim decision and power.

Keywords:  Adaptive design; Decision rule; Subpopulation

Mesh:

Substances:

Year:  2014        PMID: 24914474     DOI: 10.1080/10543406.2014.929583

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  4 in total

Review 1.  Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.

Authors:  Thomas Ondra; Alex Dmitrienko; Tim Friede; Alexandra Graf; Frank Miller; Nigel Stallard; Martin Posch
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

2.  Optimizing Trial Designs for Targeted Therapies.

Authors:  Thomas Ondra; Sebastian Jobjörnsson; Robert A Beckman; Carl-Fredrik Burman; Franz König; Nigel Stallard; Martin Posch
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

3.  Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.

Authors:  Thomas Burnett; Pavel Mozgunov; Philip Pallmann; Sofia S Villar; Graham M Wheeler; Thomas Jaki
Journal:  BMC Med       Date:  2020-11-19       Impact factor: 8.775

4.  Adaptive enrichment trials: What are the benefits?

Authors:  Thomas Burnett; Christopher Jennison
Journal:  Stat Med       Date:  2020-11-26       Impact factor: 2.373

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.